- Home
- SHMD vs ANTX Comparison
SHMD vs ANTX Comparison
Compare SHMD & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | ANTX |
|---|---|---|
| Founded | 1864 | 2017 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 172.9M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SHMD | ANTX |
|---|---|---|
| Price | $2.12 | $4.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 821.2K | 246.1K |
| Earning Date | 11-25-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.82 | N/A |
| Revenue Next Year | $48.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $1.00 |
| 52 Week High | $10.65 | $7.19 |
Technical Indicators
Market Signals| Indicator | SHMD | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 56.40 |
| Support Level | $2.09 | $3.89 |
| Resistance Level | $3.65 | $5.11 |
| Average True Range (ATR) | 0.25 | 0.40 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 2.83 | 75.37 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.